Handa's Generic Dexilant Infringes Takeda IP, Judge Hears

By Beth Winegarner (June 5, 2013, 4:29 PM EDT) -- Handa Pharmaceuticals should be blocked from making a generic version of the acid-reflux drug Dexilant because the drug cannot be produced without infringing Takeda Pharmaceutical Co.'s patented manufacturing process, Takeda argued Wednesday at the opening of a bench trial on Takeda's patent claims....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!